IP Verse

Semaglutide In Cardiovascular Conditions

Patent No. EP3448416 (titled "Semaglutide In Cardiovascular Conditions") was filed by Novo Nordisk on Apr 28, 2017. The application was issued on Aug 10, 2022.

Patent Summary

Management of high cardiovascular risk in subjects with type 2 diabetes mellitus and high cardiovascular risk. The management includes reducing the risk of myocardial infarction or stroke in subjects having type 2 diabetes mellitus and high cardiovascular risk, as well as preventing cardiovascular events in subjects with type 2 diabetes.

Patent Family

Patent Family

Patent Oppositions (8)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
APPLEYARD LEESMay 10, 2023APPLEYARD LEES
DR SCHONMay 10, 2023DR SCHON
GENERICS UKMay 10, 2023TER MEER STEINMEISTER & PARTNER
ADALVOMay 9, 2023BRAND MURRAY FULLER
ELKINGTON AND FIFEMay 9, 2023ELKINGTON AND FIFE
SANDOZMay 9, 2023ELKINGTON AND FIFE
TEVA PHARMACEUTICALSMay 9, 2023KRAUS & LEDERER PARTGMBB
STADA ARZNEIMITTELMay 5, 2023HAMM & WITTKOPP

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3448416

NOVO NORDISK
Application Number
EP17721109A
Filing Date
Apr 28, 2017
Status
Granted And Under Opposition
Jul 8, 2022
Publication Date
Aug 10, 2022
External Links
Slate, Register , Google Patents